Literature DB >> 15827116

Late-onset motoneuron disease caused by a functionally modified AMPA receptor subunit.

Rohini Kuner1, Anthony J Groom, Iris Bresink, Hans-Christian Kornau, Vanya Stefovska, Gerald Müller, Bettina Hartmann, Karsten Tschauner, Stefan Waibel, Albert C Ludolph, Chrysanthy Ikonomidou, Peter H Seeburg, Lechoslaw Turski.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a devastating disorder of the central nervous system in middle and old age that leads to progressive loss of spinal motoneurons. Transgenic mice overexpressing mutated human Cu(2+)/Zn(2+) superoxide dismutase 1 (SOD1) reproduce clinical features of the familial form of ALS. However, changes in SOD1 activity do not correlate with severity of motor decline in sporadic cases, indicating that targets unrelated to superoxide metabolism contribute to the pathogenesis of the disease. We show here that transgenic expression in mice of GluR-B(N)-containing L-alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionate (AMPA) receptors with increased Ca(2+) permeability leads to late-onset degeneration of neurons in the spinal cord and decline of motor functions. Neuronal death progresses over the entire lifespan but manifests clinically in late adulthood, resembling the course of a slow neurodegenerative disorder. Additional transgenic expression of mutated human SOD1 accelerates disease progression, aggravates the severity of motor decline, and decreases survival. These observations link persistently elevated Ca(2+) influx through AMPA channels with progressive motor decline and late-onset degeneration of spinal motoneurons, indicating that functionally altered AMPA channels may be causally related to pathogenesis of sporadic ALS in humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15827116      PMCID: PMC556301          DOI: 10.1073/pnas.0501316102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

Review 1.  Central nervous system control of food intake.

Authors:  M W Schwartz; S C Woods; D Porte; R J Seeley; D G Baskin
Journal:  Nature       Date:  2000-04-06       Impact factor: 49.962

Review 2.  Amyotrophic lateral sclerosis.

Authors:  L P Rowland; N A Shneider
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

Review 3.  The sinister side of Italian soccer.

Authors:  Simone Beretta; Maria Teresa Carri; Ettore Beghi; Adriano Chiò; Carlo Ferrarese
Journal:  Lancet Neurol       Date:  2003-11       Impact factor: 44.182

4.  Glutamate receptors: RNA editing and death of motor neurons.

Authors:  Yukio Kawahara; Kyoko Ito; Hui Sun; Hitoshi Aizawa; Ichiro Kanazawa; Shin Kwak
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

5.  Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model.

Authors:  Minako Tateno; Hisako Sadakata; Mika Tanaka; Shigeyoshi Itohara; Ryong-Moon Shin; Masami Miura; Masao Masuda; Toshihiko Aosaki; Makoto Urushitani; Hidemi Misawa; Ryosuke Takahashi
Journal:  Hum Mol Genet       Date:  2004-08-04       Impact factor: 6.150

6.  Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models.

Authors:  Ghanashyam D Ghadge; Barbara S Slusher; Amos Bodner; Mauro Dal Canto; Krystyna Wozniak; Ajit G Thomas; Camilo Rojas; Takashi Tsukamoto; Pavel Majer; Richard J Miller; Anna Liza Monti; Raymond P Roos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-22       Impact factor: 11.205

7.  Sporadic amyotrophic lateral sclerosis with circumscribed temporal atrophy: a report of an autopsy case without dementia and with ubiquitinated intraneuronal inclusions.

Authors:  Kuniaki Tsuchiya; Matuu Takahashi; Hidetoshi Shiotsu; Haruhiko Akiyama; Chie Haga; Sadakiyo Watabiki; Kazuhito Taki; Imaharu Nakano; Kenji Ikeda
Journal:  Neuropathology       Date:  2002-12       Impact factor: 1.906

Review 8.  Unraveling the mechanisms involved in motor neuron degeneration in ALS.

Authors:  Lucie I Bruijn; Timothy M Miller; Don W Cleveland
Journal:  Annu Rev Neurosci       Date:  2004       Impact factor: 12.449

9.  SOD1 mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate transporter.

Authors:  D Trotti; A Rolfs; N C Danbolt; R H Brown; M A Hediger
Journal:  Nat Neurosci       Date:  1999-05       Impact factor: 24.884

10.  alpha-Amino-3-hydroxy-5-methyl-isoxazole-4-propionate receptors in spinal cord motor neurons are altered in transgenic mice overexpressing human Cu,Zn superoxide dismutase (Gly93-->Ala) mutation.

Authors:  M Pieri; C Gaetti; A Spalloni; S Cavalcanti; N Mercuri; G Bernardi; P Longone; C Zona
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

View more
  29 in total

Review 1.  Inhibitory synaptic regulation of motoneurons: a new target of disease mechanisms in amyotrophic lateral sclerosis.

Authors:  Lee J Martin; Qing Chang
Journal:  Mol Neurobiol       Date:  2011-11-10       Impact factor: 5.590

2.  Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials.

Authors:  Albert C Ludolph; Sarah Jesse
Journal:  Ther Adv Neurol Disord       Date:  2009-09       Impact factor: 6.570

Review 3.  A-to-I RNA editing and human disease.

Authors:  Stefan Maas; Yukio Kawahara; Kristen M Tamburro; Kazuko Nishikura
Journal:  RNA Biol       Date:  2006-01-12       Impact factor: 4.652

4.  Exposure of neurons to excitotoxic levels of glutamate induces cleavage of the RNA editing enzyme, adenosine deaminase acting on RNA 2, and loss of GLUR2 editing.

Authors:  S S Mahajan; K H Thai; K Chen; E Ziff
Journal:  Neuroscience       Date:  2011-05-19       Impact factor: 3.590

Review 5.  EAAT2 and the Molecular Signature of Amyotrophic Lateral Sclerosis.

Authors:  Lauren Taylor Rosenblum; Davide Trotti
Journal:  Adv Neurobiol       Date:  2017

6.  Intrathecal infusion of a Ca(2+)-permeable AMPA channel blocker slows loss of both motor neurons and of the astrocyte glutamate transporter, GLT-1 in a mutant SOD1 rat model of ALS.

Authors:  Hong Z Yin; Darryl T Tang; John H Weiss
Journal:  Exp Neurol       Date:  2007-07-24       Impact factor: 5.330

Review 7.  Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases.

Authors:  Giulietta Riboldi; Chiara Zanetta; Michela Ranieri; Monica Nizzardo; Chiara Simone; Francesca Magri; Nereo Bresolin; Giacomo P Comi; Stefania Corti
Journal:  Mol Neurobiol       Date:  2014-05-09       Impact factor: 5.590

8.  Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity.

Authors:  Pingwei Zhao; Sheila Ignacio; Eric C Beattie; Mary E Abood
Journal:  Eur J Neurosci       Date:  2008-02       Impact factor: 3.386

9.  Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity.

Authors:  Philip Van Damme; Elke Bogaert; Maarten Dewil; Nicole Hersmus; Dora Kiraly; Wendy Scheveneels; Ilse Bockx; Dries Braeken; Nathalie Verpoorten; Kristien Verhoeven; Vincent Timmerman; Paul Herijgers; Geert Callewaert; Peter Carmeliet; Ludo Van Den Bosch; Wim Robberecht
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-05       Impact factor: 11.205

Review 10.  Dynamic regulation of RNA editing of ion channels and receptors in the mammalian nervous system.

Authors:  Bao Zhen Tan; Hua Huang; Runyi Lam; Tuck Wah Soong
Journal:  Mol Brain       Date:  2009-05-29       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.